Literature DB >> 22027949

Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients.

Andreas Keller1, Christina Backes, Petra Leidinger, Nathalie Kefer, Valesca Boisguerin, Catalin Barbacioru, Britta Vogel, Mark Matzas, Hanno Huwer, Hugo A Katus, Cord Stähler, Benjamin Meder, Eckart Meese.   

Abstract

MicroRNAs (miRNAs) are increasingly envisaged as biomarkers for various tumor and non-tumor diseases. MiRNA biomarker identification is, as of now, mostly performed in a candidate approach, limiting discovery to annotated miRNAs and ignoring unknown ones with potential diagnostic value. Here, we applied high-throughput SOLiD transcriptome sequencing of miRNAs expressed in human peripheral blood of patients with lung cancer. We developed a bioinformatics pipeline to generate profiles of miRNA markers and to detect novel miRNAs with diagnostic information. Applying our approach, we detected 76 previously unknown miRNAs and 41 novel mature forms of known precursors. In addition, we identified 32 annotated and seven unknown miRNAs that were significantly altered in cancer patients. These results demonstrate that deep sequencing of small RNAs bears high potential to quantify miRNAs in peripheral blood and to identify previously unknown miRNAs serving as biomarker for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22027949     DOI: 10.1039/c1mb05353a

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  33 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

2.  Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing.

Authors:  Jie Ma; Kaiissar Mannoor; Lu Gao; Afang Tan; Maria A Guarnera; Min Zhan; Amol Shetty; Sanford A Stass; Lingxiao Xing; Feng Jiang
Journal:  Mol Oncol       Date:  2014-04-15       Impact factor: 6.603

Review 3.  The Role of Non-coding RNAs in Oncology.

Authors:  Frank J Slack; Arul M Chinnaiyan
Journal:  Cell       Date:  2019-11-14       Impact factor: 41.582

4.  The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma.

Authors:  Lucy F Stead; Stefano Berri; Henry M Wood; Philip Egan; Caroline Conway; Catherine Daly; Kostas Papagiannopoulos; Pamela Rabbitts
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

Review 5.  Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies.

Authors:  Viswam S Nair; Colin C Pritchard; Muneesh Tewari; John P A Ioannidis
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897

Review 6.  MicroRNAs as lung cancer biomarkers.

Authors:  Valerio Del Vescovo; Margherita Grasso; Mattia Barbareschi; Michela A Denti
Journal:  World J Clin Oncol       Date:  2014-10-10

7.  Glucose depletion activates mmu-miR-466h-5p expression through oxidative stress and inhibition of histone deacetylation.

Authors:  Aliaksandr Druz; Michael Betenbaugh; Joseph Shiloach
Journal:  Nucleic Acids Res       Date:  2012-05-25       Impact factor: 16.971

8.  MicroRNA expression profiles of whole blood in lung adenocarcinoma.

Authors:  Santosh K Patnaik; Sai Yendamuri; Eric Kannisto; John C Kucharczuk; Sunil Singhal; Anil Vachani
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

9.  Treatment-independent miRNA signature in blood of Wilms tumor patients.

Authors:  Jana Schmitt; Christina Backes; Nasenien Nourkami-Tutdibi; Petra Leidinger; Stephanie Deutscher; Markus Beier; Manfred Gessler; Norbert Graf; Hans-Peter Lenhof; Andreas Keller; Eckart Meese
Journal:  BMC Genomics       Date:  2012-08-07       Impact factor: 3.969

10.  Bioinformatics of Cancer ncRNA in High Throughput Sequencing: Present State and Challenges.

Authors:  Natasha Andressa Nogueira Jorge; Carlos Gil Ferreira; Fabio Passetti
Journal:  Front Genet       Date:  2012-12-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.